Drugs / Melphalan
last change 3 days ago re-read 2 minutes ago

Melphalan

Small molecule

Developed for
plasma cell myeloma · lymphoma · myelodysplastic syndrome · leukemia · neuroblastoma · acute myeloid leukemia · Hodgkins lymphoma · chronic lymphocytic leukemia/small lymphocytic lymphoma
+224 more · disease related to hematopoietic stem cell transplant · chronic myeloid leukemia · non-Hodgkin lymphoma · retinoblastoma · breast cancer · mantle cell lymphoma · metastatic malignant neoplasm · plasma cell neoplasm · Ewing sarcoma · sarcoma · acute lymphoblastic leukemia · chronic myelomonocytic leukemia · cutaneous melanoma · myelofibrosis · plasma cell leukemia · adult acute lymphoblastic leukemia · Burkitt lymphoma · cancer of unknown primary site · colorectal cancer · follicular lymphoma · immunodeficiency disease · juvenile myelomonocytic leukemia · ovarian cancer · primary systemic amyloidosis · soft tissue sarcoma · uveal melanoma · Waldenstrom macroglobulinemia · aplastic anemia · central nervous system neoplasm · childhood acute myeloid leukemia · childhood malignant neoplasm · hematopoietic and lymphoid cell neoplasm · medulloblastoma · myelodysplastic/myeloproliferative disease · acute myeloid leukemia with 11q23 abnormalities · acute myeloid leukemia with t(8;21)(q22;q22) translocation · adult T-cell leukemia/lymphoma · amyloidosis · anaplastic large cell lymphoma · bone marrow failure syndrome · childhood acute lymphoblastic leukemia · chronic granulomatous disease · extranodal nasal NK/T cell lymphoma · Fanconi anemia · grade III lymphomatoid granulomatosis · large-cell immunoblastic lymphoma · leukemia, myeloid, accelerated-phase · light chain deposition disease · liver cancer · MALT lymphoma · melanoma · metastatic neoplasm · nodal marginal zone B-cell lymphoma · ocular melanoma · paroxysmal nocturnal hemoglobinuria · peripheral T-cell lymphoma, not otherwise specified · primary cutaneous T-cell non-Hodgkin lymphoma · smoldering plasma cell myeloma · splenic marginal zone lymphoma · supratentorial primitive neuroectodermal tumor · Wiskott-Aldrich syndrome · acquired polycythemia vera · acute biphenotypic leukemia · acute leukemia · acute myeloid leukemia with multilineage dysplasia · AL amyloidosis · angioimmunoblastic T-cell lymphoma · atypical chronic myeloid leukemia, BCR-ABL1 negative · atypical teratoid rhabdoid tumor · brain cancer · Chediak-Higashi syndrome · childhood myelodysplastic syndrome · choroid plexus carcinoma · common variable immunodeficiency · ganglioneuroblastoma · germ cell tumor · hepatoblastoma · hepatosplenic T-cell lymphoma · HIV infectious disease · hyper-IgM syndrome · immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome · intrahepatic cholangiocarcinoma · intraocular retinoblastoma · kidney cancer · Langerhans cell histiocytosis · liver and intrahepatic bile duct neoplasm · malignant testicular germ cell tumor · mycosis fungoides and variants · myeloproliferative neoplasm, unclassifiable · primary myelofibrosis · primitive neuroectodermal tumor · rhabdomyosarcoma · severe combined immunodeficiency · sickle cell disease · therapy related acute myeloid leukemia and myelodysplastic syndrome · unilateral retinoblastoma · X-linked lymphoproliferative syndrome · acute leukemia of ambiguous lineage · acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) · acute myeloid leukemia, del(5q31-q32) · acute myeloid leukemia, t(15;17)(q24;q21) · acute myeloid leukemia, t(16;16)(p13.1;q22) · acute undifferentiated leukemia · adult central nervous system germ cell tumor · aggressive B-cell non-Hodgkin lymphoma · alveolar soft part sarcoma · anaplastic ependymoma · anaplastic oligoastrocytoma · anaplastic oligodendroglioma · anemia · atypical choroid plexus papilloma · autoimmune lymphoproliferative syndrome · B-cell chronic lymphocytic leukemia · benign neoplasm · beta thalassemia · beta-thalassemia major · bilateral retinoblastoma · brain neoplasm · bronchiectasis · Bruton-type agammaglobulinemia · castration-resistant prostate carcinoma · central nervous system germ cell tumor · central nervous system vasculitis · cerebellar degeneration · childhood brain stem glioma · childhood central nervous system germ cell tumor · childhood cerebellar astrocytic neoplasm · childhood cerebral astrocytoma · childhood ependymoma · childhood medulloblastoma · childhood supratentorial embryonal tumor with multilayered rosettes, C19MC-altered · chronic eosinophilic leukemia · chronic inflammatory demyelinating polyradiculoneuropathy · chronic neutrophilic leukemia · colorectal neoplasm · congenital amegakaryocytic thrombocytopenia · COVID-19 · Diamond-Blackfan anemia · diffuse intrinsic pontine glioma · diffuse large B-cell lymphoma · DiGeorge syndrome · eccrine carcinoma · Epstein-Barr virus infection · essential thrombocythemia · Ewing sarcoma of bone · Ewing sarcoma/peripheral primitive neuroectodermal tumor · extragonadal germ cell tumor · extragonadal nonseminomatous germ cell tumor · extramedullary plasmacytoma · extraocular retinoblastoma · extraskeletal Ewing sarcoma · female breast carcinoma · hairy cell leukemia · hematologic disorder · hemoglobinopathy · hemophagocytic syndrome · hepatocellular carcinoma · histiocytosis · hyper-IgM syndrome type 1 · idiopathic aplastic anemia · immune dysregulation, autoimmunity, and autoinflammation · inborn errors of metabolism · inflammatory breast carcinoma · kidney neoplasm · Lambert-Eaton myasthenic syndrome · large B-cell lymphoma · leukocyte adhesion deficiency · lymphoid neoplasm · lymphoplasmacytic lymphoma · malignant childhood germ cell neoplasm · malignant germ cell tumor · marginal zone lymphoma · mature T-cell and NK-cell non-Hodgkin lymphoma · medulloepithelioma · metastasis from malignant tumor of colon · metastatic malignant neoplasm in the spinal cord · metastatic melanoma · mixed phenotype acute leukemia · myasthenia gravis · myeloid sarcoma · myeloproliferative neoplasm · myxofibrosarcoma · neoplasm · neuroendocrine carcinoma · neuromyelitis optica · opsoclonus-myoclonus syndrome · optic pathway glioma · ovarian carcinoma · ovarian mixed germ cell neoplasm · pancreatic neuroendocrine tumor · pediatric intraocular retinoblastoma · Philadelphia-positive myelogenous leukemia · pineoblastoma · post-transplant lymphoproliferative disease · premalignant hematological system disease · prolymphocytic leukemia · prostate cancer · Rasmussen subacute encephalitis · rectal cancer · refractory malignant neoplasm · refractory plasma cell neoplasm · relapsing-remitting multiple sclerosis · renal cell carcinoma · severe congenital neutropenia · Shwachman-Diamond syndrome · skin basal cell carcinoma · skin squamous cell carcinoma · small intestine cancer · solitary osseous plasmacytoma · stiff-person syndrome · T-cell large granular lymphocyte leukemia · T-cell non-Hodgkin lymphoma · testicular cancer · thalassemia · undifferentiated pleomorphic sarcoma · urinary bladder cancer · urothelial carcinoma · viral pneumonia · Wilms tumor · breast carcinoma · cancer · lymphoid leukemia · malignant pancreatic neoplasm · myelodysplastic/myeloproliferative neoplasm
Investigated by
National Cancer Institute (NCI) · M.D. Anderson Cancer Center · Memorial Sloan Kettering Cancer Center · City of Hope Medical Center · Fred Hutchinson Cancer Center · Children's Oncology Group
+273 more · Delcath Systems Inc. · Masonic Cancer Center, University of Minnesota · Celgene Corporation · Roswell Park Cancer Institute · SWOG Cancer Research Network · University of Maryland, Baltimore · Boston Medical Center · Children's Cancer and Leukaemia Group · H. Lee Moffitt Cancer Center and Research Institute · Medical College of Wisconsin · University of Arkansas · Washington University School of Medicine · Fondazione EMN Italy Onlus · Herbert Irving Comprehensive Cancer Center · Mayo Clinic · National Institutes of Health Clinical Center (CC) · Amgen · Cancer Research UK · Duke University · Eastern Cooperative Oncology Group · European Organisation for Research and Treatment of Cancer - EORTC · German Society for Pediatric Oncology and Hematology GPOH gGmbH · Gustave Roussy, Cancer Campus, Grand Paris · Institute of Hematology & Blood Diseases Hospital, China · Millennium Pharmaceuticals, Inc. · National Marrow Donor Program · OHSU Knight Cancer Institute · Samsung Medical Center · Seoul National University Hospital · Shanghai Jiao Tong University School of Medicine · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · University of California, San Francisco · University of Chicago · University of Maryland Greenebaum Cancer Center · Weill Medical College of Cornell University · Alliance for Clinical Trials in Oncology · Blood and Marrow Transplant Clinical Trials Network · EBMT Solid Tumors Working Party · Inje University · Institut Curie · National Heart, Lung, and Blood Institute (NHLBI) · New Approaches to Neuroblastoma Therapy Consortium · Oncotherapeutics · PETHEMA Foundation · Stanford University · Swiss Cancer Institute · University of Nebraska · Acrotech Biopharma Inc. · Albert Einstein College of Medicine · Ann & Robert H Lurie Children's Hospital of Chicago · Asan Medical Center · Austrian Forum Against Cancer · Barbara Ann Karmanos Cancer Institute · Children's Hospital Medical Center, Cincinnati · Children's Hospital of Philadelphia · Federal State Budgetary Institution, Pulmonology Scientific Research Institute · Fondation Rothschild Paris · French Innovative Leukemia Organisation · Hackensack Meridian Health · Hadassah Medical Organization · Insel Gruppe AG, University Hospital Bern · Janssen Research & Development, LLC · Massachusetts General Hospital · Medical Research Council · Ministry of Health, France · Moscow State University of Medicine and Dentistry · National Institutes of Health (NIH) · Oregon Health and Science University · Otsuka Pharmaceutical Development & Commercialization, Inc. · Second Affiliated Hospital, School of Medicine, Zhejiang University · Severance Hospital · SmithKline Beecham · Societe Francaise Oncologie Pediatrique · St. Petersburg State Pavlov Medical University · all 279 on the full record

Regulatory milestones approvals, filings & regulatory actions · 2 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved EU (EMA) Phelinun 2020-11-16 europa.eu
Approved US (FDA) ALKERAN 1964-01-17 fda.gov

Trials 412 · started per year

today
US approved 1964
EU approved 2020
1
1
2
3
6
2
4
14
20
20
12
20
9
4
18
14
17
18
22
21
15
18
13
18
10
8
9
13
11
8
6
16
5
10
7
4
7
1
19631964196519661967196819691970197119721973197419751976197719781979198019811982198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 02 trials
Phase 0 NCT05013437 Sep → Dec 2023 plasma cell myeloma Koen van Besien Withdrawn No outcome recorded
Phase 0 NCT02109861 Jan 2014 → Dec 2015 plasma cell myeloma Henrik Gregersen Unknown No outcome recorded
Phase 145 trials
Phase 1 NCT04466475 Jan 2024 → Oct 2025 plasma cell myeloma Fred Hutchinson Cancer Center Withdrawn No outcome recorded
Phase 1 NCT04994977 May 2023 → Jul 2024 atypical choroid plexus papilloma, choroid plexus carcinoma Weill Medical College of Cornell University Terminated No outcome recorded
Phase 1 NCT05438394 Oct 2022 → Dec 2023 plasma cell myeloma Peking University People's Hospital Unknown No outcome recorded
Phase 1 NCT05088356 Sep 2021 → May 2028 expected acute leukemia, chronic myeloid leukemia, disease related to hematopoietic stem cell transplant, myelodysplastic syndrome Stanford University Active not recruiting No outcome recorded
Phase 1 NCT04483206 May 2021 → Jun 2027 expected plasma cell myeloma Emory University Recruiting No outcome recorded
Phase 1 NCT04521946 Jan 2021 → Dec 2022 anaplastic ependymoma, atypical teratoid rhabdoid tumor, central nervous system germ cell tumor, choroid plexus carcinoma +3 M.D. Anderson Cancer Center Withdrawn No outcome recorded
Phase 1 NCT04150042 Jan 2021 → Dec 2028 expected BRCA1-related cancer predisposition, BRCA2-related cancer predisposition, Her2-receptor negative breast cancer, PALB2-related cancer predisposition +3 General Oncology, Inc. Recruiting No outcome recorded
Phase 1 NCT04937634 Sep 2020 → Sep 2023 disease related to hematopoietic stem cell transplant Seoul National University Hospital Unknown No outcome recorded
Phase 1 NCT04342572 Aug 2020 → Jan 2023 retinoblastoma Washington University School of Medicine Completed No outcome recorded
Phase 1 NCT04098393 Sep 2019 → Sep 2026 expected hematopoietic and lymphoid cell neoplasm Memorial Sloan Kettering Cancer Center Active not recruiting No outcome recorded
Phase 1/249 trials
Phase 1/2 NCT07281924 Jul 2026 → Dec 2030 expected metastatic melanoma University of Wisconsin, Madison Recruiting No outcome recorded
Phase 1/2 NCT06158828 Nov 2024 → Sep 2028 expected acute myeloid leukemia by FAB classification, childhood acute myeloid leukemia Washington University School of Medicine Recruiting No outcome recorded
Phase 1/2 NCT05508009 Jan 2023 → Oct 2032 expected chronic kidney disease, cystinosis, focal segmental glomerulosclerosis, lupus nephritis Alice Bertaina Recruiting No outcome recorded
Phase 1/2 NCT05893654 May 2021 → Dec 2025 overdue uveal melanoma Hospital das Clínicas de Ribeirão Preto Enrolling by invitation No outcome recorded
Phase 1/2 NCT04283890 Dec 2019 → Dec 2026 expected uveal melanoma Leiden University Medical Center Active not recruiting No outcome recorded
Phase 1/2 NCT03417284 Oct 2019 → Jul 2024 plasma cell myeloma M.D. Anderson Cancer Center Completed No outcome recorded
Phase 1/2 NCT03795597 May 2019 → Nov 2022 plasma cell myeloma Loyola University Unknown No outcome recorded
Phase 1/2 NCT03100877 Jan 2018 → May 2020 plasma cell leukemia, plasma cell myeloma City of Hope Medical Center Withdrawn No outcome recorded
Phase 1/2 NCT03192397 Aug 2017 → Aug 2023 overdue Hodgkins lymphoma, Philadelphia-positive myelogenous leukemia, Waldenstrom macroglobulinemia, acute myeloid leukemia +6 Roswell Park Cancer Institute Active not recruiting No outcome recorded
Phase 1/2 NCT03259516 May 2017 → Dec 2018 myelodysplastic syndrome St. Petersburg State Pavlov Medical University Terminated No outcome recorded
Phase 2219 trials
Phase 2 NCT07582172 Apr 2027 → Apr 2029 expected acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome City of Hope Medical Center Not yet recruiting No outcome recorded
Phase 2 NCT07029776 Jul 2026 → Apr 2030 expected plasma cell myeloma University of Arkansas Not yet recruiting No outcome recorded
Phase 2 NCT05565105 Jun 2026 → Jun 2033 expected acute lymphoblastic leukemia, acute myeloid leukemia Guenther Koehne Not yet recruiting No outcome recorded
Phase 2 NCT07481669 Mar 2026 → Mar 2028 expected lymphoma Second Affiliated Hospital, School of Medicine, Zhejiang University Recruiting No outcome recorded
Phase 2 NCT06875128 Jan 2026 → May 2029 expected Delcath Systems Inc. Recruiting No outcome recorded
Phase 2 NCT07276386 Dec 2025 → Dec 2030 expected uveal melanoma H. Lee Moffitt Cancer Center and Research Institute Recruiting No outcome recorded
Phase 2 NCT06607458 Aug 2025 → Dec 2026 expected colorectal cancer Delcath Systems Inc. Recruiting No outcome recorded
Phase 2 NCT07085156 Aug 2025 → May 2028 expected myelodysplastic syndrome Ruijin Hospital Not yet recruiting No outcome recorded
Phase 2 NCT07078721 Jul 2025 → Jan 2028 expected idiopathic aplastic anemia Institute of Hematology & Blood Diseases Hospital, China Not yet recruiting No outcome recorded
Phase 2 NCT06679829 Nov 2024 → Nov 2027 expected plasma cell myeloma Memorial Sloan Kettering Cancer Center Recruiting No outcome recorded
Show all 219 trials opens the full record — a long page
Phase 2/37 trials
Phase 2/3 NCT04681417 Mar 2021 → Jan 2035 expected retinoblastoma Institut Curie Recruiting No outcome recorded
Phase 2/3 NCT03086993 Apr 2018 → Jan 2023 intrahepatic cholangiocarcinoma Delcath Systems Inc. Unknown No outcome recorded
Phase 2/3 NCT01907009 Jan 2013 → Dec 2016 castration-resistant prostate carcinoma Barts & The London NHS Trust Terminated No outcome recorded
Phase 2/3 NCT00454480 Aug 2006 → Aug 2012 leukemia, myelodysplastic syndrome The University of New South Wales Completed No outcome recorded
Phase 2/3 NCT00177047 Apr 2004 → Aug 2020 plasma cell myeloma Masonic Cancer Center, University of Minnesota Completed No outcome recorded
Phase 2/3 NCT00205751 Aug 2001 → Oct 2009 plasma cell myeloma Austrian Forum Against Cancer Completed No outcome recorded
Phase 2/3 NCT00003816 Oct 1998 → Jul 2019 benign neoplasm, childhood malignant neoplasm, leukemia, lymphoma +3 Roswell Park Cancer Institute Completed No outcome recorded
Phase 358 trials
Phase 3 NCT06613035 Sep 2024 → Sep 2027 expected acute myeloid leukemia Institute of Hematology & Blood Diseases Hospital, China Not yet recruiting No outcome recorded
Phase 3 NCT06022939 Jul 2024 → Jul 2030 expected AL amyloidosis SWOG Cancer Research Network Recruiting No outcome recorded
Phase 3 NCT06829472 Dec 2023 → Jul 2026 overdue chemotherapy-induced toxicity Shanghai Jiao Tong University School of Medicine Recruiting No outcome recorded
Phase 3 NCT05991908 Oct 2023 → Oct 2025 overdue acute myeloid leukemia, myelodysplastic syndrome Shanghai Jiao Tong University School of Medicine Recruiting No outcome recorded
Phase 3 NCT05674539 Feb 2023 → Dec 2025 overdue acute myeloid leukemia, disease related to hematopoietic stem cell transplant, myelodysplastic syndrome Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Enrolling by invitation No outcome recorded
Phase 3 NCT05022901 Jun 2022 → Mar 2024 overdue uveal melanoma Delcath Systems Inc. Active not recruiting No outcome recorded
Phase 3 NCT04799002 Mar 2021 → Dec 2024 overdue chemotherapy-induced toxicity, retinoblastoma Sun Yat-sen University Recruiting No outcome recorded
Phase 3 NCT04221035 Nov 2019 → Nov 2026 expected neuroblastoma Gustave Roussy, Cancer Campus, Grand Paris Recruiting No outcome recorded
Phase 3 NCT03126916 May 2018 → Sep 2030 expected neuroblastoma, nodular ganglioneuroblastoma Children's Oncology Group Recruiting No outcome recorded
Phase 3 NCT02858258 Jul 2016 → May 2021 mantle cell lymphoma Prof. Dr. M. Dreyling (co-chairman) Unknown No outcome recorded
Phase 44 trials
Phase 4 NCT06425276 Jul 2020 → Jul 2021 plasma cell myeloma CASI Pharmaceuticals (China) Co., Ltd. Completed No outcome recorded
Phase 4 NCT03829371 Jan 2019 → Jan 2027 expected plasma cell myeloma University of Turin, Italy Active not recruiting No outcome recorded
Phase 4 NCT02773550 Jan 2014 → Jul 2018 plasma cell myeloma Basque Health Service Terminated No outcome recorded
Phase 4 NCT00652041 Jan 2007 → Jan 2010 plasma cell myeloma PETHEMA Foundation Completed No outcome recorded
Phase not applicable25 trials
NCT07644481 Jul 2026 → Dec 2029 expected acute myeloid leukemia, disease related to hematopoietic stem cell transplant Institute of Hematology & Blood Diseases Hospital, China Not yet recruiting No outcome recorded
NCT07364474 Jan 2026 → Dec 2027 expected uveal melanoma Massachusetts General Hospital Recruiting No outcome recorded
NCT04903678 May 2021 → May 2028 expected extraocular retinoblastoma Eye & ENT Hospital of Fudan University Recruiting No outcome recorded
NCT04008888 Jan 2018 → Jan 2020 chromosome 17p deletion, extramedullary soft tissue plasmacytoma, plasma cell leukemia, plasma cell myeloma Institute of Hematology & Blood Diseases Hospital, China Unknown No outcome recorded
NCT02551718 Sep 2015 → Jun 2020 acute leukemia of ambiguous lineage, acute lymphoblastic leukemia University of Washington Completed No outcome recorded
NCT01795430 Jul 2013 → Mar 2018 Ewing sarcoma of bone, extraskeletal Ewing sarcoma, supratentorial primitive neuroectodermal tumor City of Hope Medical Center Withdrawn No outcome recorded
NCT01652092 Sep 2012 → Dec 2025 overdue Chediak-Higashi syndrome, Griscelli syndrome, Langerhans cell histiocytosis, Omenn syndrome +6 Masonic Cancer Center, University of Minnesota Active not recruiting No outcome recorded
NCT02507076 Apr 2012 → Jul 2014 eccrine carcinoma, melanoma, skin basal cell carcinoma, skin squamous cell carcinoma +1 Albert Einstein College of Medicine Withdrawn No outcome recorded
NCT01558960 Mar 2012 → Aug 2015 retinoblastoma Hadassah Medical Organization Terminated No outcome recorded
NCT01572688 Nov 2011 → Jun 2014 plasma cell myeloma Shandong Lanjin Pharmaceuticals Co.,Ltd Unknown No outcome recorded
Phase not stated3 trials
NCT00799539 plasma cell myeloma Janssen-Ortho Inc., Canada No longer available No outcome recorded
NCT01728051 cutaneous melanoma, liver cancer, ocular melanoma Delcath Systems Inc. No longer available No outcome recorded
NCT01250808 plasma cell myeloma Peking University Available No outcome recorded
Also used as a comparator or background therapy in 364 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 05 trials
Phase 0 NCT04264078 Background Mar 2021 → Jun 2022 T-cell leukemia, T-cell non-Hodgkin lymphoma Xinqiao Hospital of Chongqing Unknown No outcome recorded
Phase 0 NCT04264039 Background Apr 2020 → Apr 2021 B-cell acute lymphoblastic leukemia Xinqiao Hospital of Chongqing Unknown No outcome recorded
Phase 0 NCT03426969 Background Jan 2018 → Sep 2020 myelofibrosis, primary myelofibrosis M.D. Anderson Cancer Center Completed No outcome recorded
Phase 0 NCT02447055 Background Dec 2015 → Jun 2016 plasma cell myeloma Washington University School of Medicine Withdrawn No outcome recorded
Phase 0 NCT02653196 Background Sep 2015 → Aug 2017 neuroepithelial neoplasm Montefiore Medical Center Terminated No outcome recorded
Phase 171 trials
Phase 1 NCT07257419 Background Aug 2026 → Dec 2031 expected childhood acute lymphoblastic leukemia, disease related to hematopoietic stem cell transplant St. Jude Children's Research Hospital Recruiting No outcome recorded
Phase 1 NCT06996119 Background Jun 2026 → May 2027 expected acute myeloid leukemia, graft versus host disease, myelodysplastic syndrome City of Hope Medical Center Recruiting No outcome recorded
Phase 1 NCT07183852 Background Mar 2026 → Mar 2028 expected cutaneous melanoma, uveal melanoma Vastra Gotaland Region Not yet recruiting No outcome recorded
Phase 1 NCT07052370 Background Sep 2025 → Dec 2028 expected hematopoietic and lymphoid system neoplasm St. Jude Children's Research Hospital Recruiting No outcome recorded
Phase 1 NCT06287944 Background Jul 2025 → May 2028 expected acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome City of Hope Medical Center Recruiting No outcome recorded
Phase 1/252 trials
Phase 1/2 NCT06986382 Background Jul 2025 → Jul 2037 expected Crohn disease Stanford University Not yet recruiting No outcome recorded
Phase 1/2 NCT05436418 Background Nov 2022 → Jun 2027 expected disease related to hematopoietic stem cell transplant National Cancer Institute (NCI) Recruiting No outcome recorded
Phase 1/2 NCT04982354 Background Jul 2022 → Aug 2031 acute myeloid leukemia Guenther Koehne Withdrawn No outcome recorded
Phase 1/2 NCT04690192 Background Jan 2021 → Dec 2023 large B-cell lymphoma Institute of Hematology & Blood Diseases Hospital, China Completed No outcome recorded
Phase 1/2 NCT04022239 Background Mar 2020 → Jul 2027 expected hematopoietic and lymphoid system neoplasm M.D. Anderson Cancer Center Recruiting No outcome recorded
Phase 2159 trials
Phase 2 NCT07605416 Background Jul 2026 → Nov 2032 expected plasma cell leukemia National Cancer Institute (NCI) Not yet recruiting No outcome recorded
Phase 2 NCT05617625 Background Jun 2026 → Jun 2033 graft versus host disease, myelodysplastic syndrome Guenther Koehne Suspended No outcome recorded
Phase 2 NCT07284641 Background May 2026 → May 2030 expected DiGeorge syndrome, GATA2 deficiency with susceptibility to MDS/AML, Omenn syndrome, STAT3-related early-onset multisystem autoimmune disease +8 Paul Szabolcs Recruiting No outcome recorded
Phase 2 NCT07228624 Background Feb 2026 → Sep 2030 expected myelodysplastic/myeloproliferative neoplasm, myelofibrosis, primary myelofibrosis Fred Hutchinson Cancer Center Recruiting No outcome recorded
Phase 2 NCT07259161 Background Dec 2025 → Sep 2029 expected blast phase chronic myelogenous leukemia, BCR-ABL1 positive Institute of Hematology & Blood Diseases Hospital, China Not yet recruiting No outcome recorded
Show all 159 trials opens the full record — a long page
Phase 2/35 trials
Phase 2/3 NCT03385096 Comparator Jan 2018 → Dec 2020 disease related to hematopoietic stem cell transplant, plasma cell myeloma Nanfang Hospital, Southern Medical University Unknown No outcome recorded
Phase 2/3 NCT02707393 Background Apr 2009 → Dec 2020 chronic myeloid leukemia St. Anna Children's Cancer Research Completed No outcome recorded
Phase 2/3 NCT00539500 Background Oct 2007 → Sep 2012 neuroblastoma M.D. Anderson Cancer Center Terminated No outcome recorded
Phase 2/3 NCT00070187 Background Nov 2003 → Jun 2005 lymphoma Children's Oncology Group Completed No outcome recorded
Phase 2/3 NCT00176839 Background Jun 2000 → Feb 2012 acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome Masonic Cancer Center, University of Minnesota Terminated No outcome recorded
Phase 352 trials
Phase 3 NCT07624513 Comparator Jun 2026 → Oct 2033 expected plasma cell myeloma Dana-Farber Cancer Institute Not yet recruiting No outcome recorded
Phase 3 NCT07396480 Comparator Mar 2026 → Jan 2030 expected acute myeloid leukemia, myelodysplastic syndrome First Affiliated Hospital of Zhejiang University Recruiting No outcome recorded
Phase 3 NCT06172296 Background Apr 2024 → Dec 2029 expected neuroblastoma, nodular ganglioneuroblastoma National Cancer Institute (NCI) Recruiting No outcome recorded
Phase 3 NCT05931263 Background Jun 2023 → Feb 2026 overdue peripheral T-cell lymphoma, not otherwise specified The First Affiliated Hospital with Nanjing Medical University Recruiting No outcome recorded
Phase 3 NCT05457556 Background Mar 2023 → Jun 2026 overdue acute lymphoblastic leukemia, mixed phenotype acute leukemia, myelodysplastic syndrome Children's Oncology Group Active not recruiting No outcome recorded
Phase 42 trials
Phase 4 NCT05518383 Background May 2022 → May 2025 overdue Burkitt lymphoma, primary central nervous system lymphoma, primary mediastinal large B-cell lymphoma Federal Research Institute of Pediatric Hematology, Oncology and Immunology Recruiting No outcome recorded
Phase 4 NCT01731886 Comparator Sep 2012 → Apr 2017 plasma cell myeloma Columbia University Completed No outcome recorded
Phase not applicable17 trials
NCT07588360 Background Oct 2025 → Oct 2028 expected acute myeloid leukemia, myelodysplastic syndrome Fujian Medical University Union Hospital Recruiting No outcome recorded
NCT05922384 Background Jul 2023 → Sep 2025 HIV infectious disease, lymphoma Affiliated Hospital of Guangdong Medical University Unknown No outcome recorded
NCT05863845 Background Jun 2023 → Nov 2024 diffuse large B-cell lymphoma Ruijin Hospital Unknown No outcome recorded
NCT05813132 Comparator Nov 2022 → Dec 2023 lymphoma Rehab Werida Completed No outcome recorded
NCT02880293 Background Aug 2016 → Nov 2023 hematopoietic and lymphoid cell neoplasm Memorial Sloan Kettering Cancer Center Completed No outcome recorded
Phase not stated1 trial
NCT01085617 Background Dec 2010 → Feb 2025 leukemia, mouth disorder, mucositis University College, London Completed No outcome recorded

Evidence & citations 36 cited values

Every value below carries the sentence it was read from. 779 sources stand behind the page.

FieldValueCited text
Known as melphalan “Induction:Carfilzomib/Lenalidomide/Dexamethasone (4 cycles every 28 days) Stem Cell harvest: HD Cyclophosphamide Intensification: HD Melphalan...” NCT02405364
763

“Study participants will receive a non-TBI based preparative regimen consisting of Cyclophosphamide, fludarabine, thiotepa, melphalan, and muromonab-CD3 (OKT3) followed by an...” NCT00145626

“Twenty-two children with a median age of 2.8 years, many with severe comorbidities and prior viral infections, were enrolled in a novel RIC protocol consisting of hydroxyurea,...” PMID 24296492 Dec 2013

“The investigator prospectively evaluated the combination of Rituximab and Dexa-BEAM (dexamethasone, carmustine, etoposide, cytarabine, melphalan) followed by high dose therapy...” NCT02099292

“Clinical and safety outcomes of BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) versus CEM (Carboplatin, Etoposide, Melphalan) in lymphoma patients as a conditioning...” PMID 39134959 Aug 2024

“Haploidentical stem cell transplant recipients will receive a reduced intensity conditioning regimen consisting of OKT-3, Fludarabine, Thiotepa , and Melphalan followed by an...” NCT00145587

“High Dose Melphalan and Autologous Hematopoietic Cell Transplantation Patients will receive Melphalan 200 mg/m2 per institutional guidelines, or if over 70 years of age or...” NCT03556332

“Transplant recipients received a reduced intensity conditioning regimen consisting of OKT-3, fludarabine, thiotepa, and melphalan followed by an infusion of a T-cell depleted...” NCT00143559

“Patients will receive busulfan twice daily on Days - 8, -7, -6, and -5 and Melphalan on Days -4, -3 and -2 and rabbit antithymocyte globulin on Days -4, -3, -2 and -1 with stem...” NCT01049854

“Once the patient recovers, the patient will be evaluated again and will then undergo a second stem cell transplant consisting of the chemotherapy drugs; Melphalan,...” NCT00179816

“Conditioning chemotherapy before infusion of allogeneic stem cells will include fludarabine 30 mg/m2/day for 5 consecutive days (days -6 to -2) and melphalan 100 mg/m2 at day -2.” NCT00772811

“Targeted total bone marrow and lymphoid irradiation (TMLI) conformal therapy administered in combination with a reduced-intensity regimen based on Fludarabine and Melphalan.” NCT06602323

“Consolidation (6 cycles): Melphalan 2 mg three times a week, Prednisone 50 mg three times a week, and Lenalidomide 15 mg/die for 21 days followed by a 7 days rest period.” NCT01160107

“Patients will receive reduced intensity chemotherapy with one of three regimens: Busulfan/Fludarabine; Gemcitabine/Fludarabine/Melphalan; Fludarabine/Cyclophosphamide” NCT02098512

“Intensive chemotherapy Cladribine-cytarabine-etoposide -venetoclax sequential with fludarabine, busulfan and melphalan or fludarabine and total marrow irradiation” NCT05870995

“This phase 1/2 dose-escalation study aimed to determine the maximum tolerated dose (MTD) of lenalidomide in combination with melphalan and dexamethasone (M-dex)” PMID 20724537 Aug 2010

“Transplant recipients received a non-TBI based reduced intensity conditioning regimen consisting of OKT-3, Fludarabine Thiotepa, and Melphalan.” NCT00145613

“Carmustine (B) also known as BCNU Etoposide (E) Cytarabine (A) also known as Ara-C and cytosine arabinoside Melphalan (M) also known as alkeran” NCT00574509

“Subjects who are MRD-positive (a threshold of 10\^5) will receive a single melphalan (MEL)-based hematopietic stem cell transplantation (HSCT)” NCT07029776

“Poor responders will undergo to stem cells apheresis and their reinfusion after treatment with high doses of Busulfan and Melphalan 25 weeks.” NCT02063022

Melphalan is given at a dose of 140 mg/m2 as an intravenous infusion over a 1 hour period on treatment day -1 (Day 0 = stem cell transplant).” NCT00058292

“A Phase II Trial of High-dose Bendamustine, Etoposide, Cytarabine, and Melphalan (BeEAM) in the Up-front Treatment of Multiple Myeloma” NCT02416206

“conditioning regimen of alemtuzumab/Campath, anti-thymocyte globulin/rabbit ATG, Fludarabine and Melphalan and total body irradiation” NCT07284641

“myeloablative chemotherapy with autologous stem cell transplantation (melphalan, carboplatin, etoposide) 9 x retinoic acid cycles” NCT03042429

“The transplant conditioning regimen will include fludarabine, melphalan, and alemtuzumab starting at Day -14 (Flu/Mel/Alem).” NCT01998633

“reduced intensity conditioning regimen consisting of Fludarabine (150mg/m2) + Busulfan (6.4mg/kg) + Melphalan (70mg/m2)” NCT04904237

“semustine 250mg/m2 PO d1; etoposide 200mg/m2 IV d2-5; cytarabine 400mg/m2 IV d2-5; melphalan 140mg/m2 IV d6.” NCT05504603

“tandem high dose melphalan (140 mg/m²) with autologous peripheral blood stem cell transplantation (PBSCT)” NCT01090089

“Clofarabine, Melphalan,Thiotepa, Cyclophosphamide, Mesna, Tacrolimus and mycophenolate mofetil (MMF)” NCT02053545

“Methylprednisolone, Equine ATG, Cyclosporine, Fludarabine, Melphalan, Thiotepa and Rituximab.” NCT00582816

“BCNU, etoposide, cytarabine and melphalan (BEAM) chemotherapy are given after 90Y-daclizumab” NCT01468311

Melphalan, another routine transplant chemotherapy will be given on day -4 as IV infusion” NCT06265584

“Chemotherapies: busulfan, fludarabine, melphalan, cyclophosphamide, thiotepa, clofarabine” NCT04761770

melphalan, 140 mg/m2 intravenously on day -1 before reinfusion of autologous stem cells” NCT02278796

“cyclophosphamide or melphalan or mitomycin C or thiotepa or cisplatin or carboplatin” NCT01091168

Melphalan (140 mg/m2 once daily i.v. on day -7, 70 mg/m2 once daily i.v. on day -6)” NCT01342237

“Fludarabine 150mg/m2, busulfan 6.4mg/kg, melphalan 100mg/m2 and etoposide 600mg/m2” NCT04897139

“RIC with alemtuzumab, fludarabine, and melphalan between March 2003 and May 2014” PMID 26348869 Oct 2015

“Reduced intensity conditioning regimen with fludarabine, busulfan and melphalanNCT05436561

“injection of TNF-α 0.3 mg followed 5 minutes later by melphalan 1,5mg/kg” NCT00949039

“day -1 Melphalan 140 mg/m2 i.v. in 100ml saline solution in 200 ml/hr” NCT01827605

“Cyclophosphamide 10 mg/kg day 1, Melphalan 0.25 mg/kg v.o. days 1-4” NCT00560053

“Cycle 2, 5, 8 etc- Melphalan 6 mg/m2 po daily on Days 1-7 days” NCT00691704

melphalan 140 mg/m2/d for 1 day administered over 15 minutes” NCT00597714

“Chidemide,carmustine, etoposide, cytarabine, and melphalanNCT05931263

“THAM (TBI (total body irradiation), Ara-C, Melphalan)” NCT02858258

Melphalan 140 mg/m2/day intravenously once on day -1” NCT03187210

Melphalan 70 mg/m\^2 IV over 30 minutes for 2 days” NCT00385788

“Alkeran (melphalan) - drug class: alkylating agent” NCT02626715

Melphalan 100 mg/m2 on day -2 and day -1” NCT02148913

Melphalan 200mg/m2 IV infusion on Day -1” NCT03562169

Melphalan: 60 mg/m² on days -8 and -7.” NCT06613035

Melphalan, 100 mg/m2 on days -4 and -1” NCT00670631

“BCNU, Etoposide, Cytarabine, MelphalanNCT03113162

Melphalan: 140 mg/m\^2 IV on Day -3” NCT00745420

“Fludarabine and melphalan (Flu/Mel)” NCT06859424

“Lomustine Melphalan Mercaptopurine” NCT02551718

melphalan: 140mg/m2 vgtt qd D3-D-2” NCT06652165

Melphalan: 140 mg/m2 IV on Day -3” NCT02776202

Melphalan: 140mg/m2 ivgtt D-3-D2” NCT06652139

melphalan 140mg/m2 IV on day -1” NCT00572013

Melphalan: 140 mg/m2 i.v. day 6” NCT00791947

Melphalan 140 mg/m², iv, day -2” NCT00946374

“Day -3: Melphalan 140 mg/m2 IV” NCT00920972

melphalan, darzalex, revlimid” NCT05231629

Melphalan, IV, D-1, 140 mg/m²” NCT03011528

Melphalan 140 mg/m2 on day -1” NCT01296256

Melphalan: 140mg/m2 ivgtt D-2” NCT05367856

Melphalan 140 mg/m2 (Day -1)” NCT00329030

“Mechlor, Melphalan, Mercapto” NCT02788201

Melphalan 140 mg/m2 on D-2” NCT02008006

“Drug: melphalan Given IV” NCT05922384

Melphalan day -3 to -2” NCT02165007

melphalan (140mg/m2)” NCT03128996

Melphalan (Alkeran™)” NCT02128230

melphalan 100mg/m2” NCT06378060

“Device: MelphalanNCT07281924

“* Melphalan (Mel)” NCT02988466

melphalan on dd 6” NCT01516593

“* MelphalanNCT00167219

MelphalanNCT00734877

NCT00006695

NCT06692452

NCT00567567

NCT01091831

NCT00019968

NCT00181025

NCT00003146

NCT00003926

NCT00005792

NCT00793845

NCT01758328

NCT03352765

NCT05564390

NCT00045136

NCT00019786

NCT01256398

NCT00019760

NCT00646750

NCT07052370

NCT00209222

NCT03385096

NCT02581007

NCT00564200

NCT01769911

NCT05565105

NCT01605032

NCT00027937

NCT00005803

NCT00857519

NCT00265889

NCT00003899

NCT03072771

NCT04455139

NCT00020566

NCT04332874

NCT00020501

NCT01907009

NCT03125642

NCT00804947

NCT00019097

NCT01818752

NCT02961816

NCT00793650

NCT00002548

NCT00692939

NCT00482846

NCT04342572

NCT03674411

NCT00429572

NCT00793572

NCT05084027

NCT00002556

NCT01531244

NCT01085617

NCT00003954

NCT00028600

NCT02435901

NCT00003957

NCT02366663

NCT01731886

NCT00469209

NCT00003972

NCT02043860

NCT00995059

NCT00571493

NCT01660633

NCT07257419

NCT00744536

NCT05518383

NCT07228624

NCT00908180

NCT00798148

NCT04483206

NCT03126916

NCT02342782

NCT03742297

NCT00017680

NCT00112827

NCT00084695

NCT03849651

NCT00096083

NCT05303727

NCT00133367

NCT03217812

NCT00028886

NCT02784015

NCT05022901

NCT01339910

NCT00017368

NCT00085345

NCT02784054

NCT00017225

NCT00002594

NCT01875237

NCT00003163

NCT03259516

NCT02043847

NCT02061800

NCT00002599

NCT01499147

NCT02504359

NCT00520767

NCT00002601

NCT01078454

NCT01962415

NCT00005835

NCT00152126

NCT00547196

NCT05893654

NCT02007863

NCT02295722

NCT06829472

NCT02472392

NCT00016887

NCT02771197

NCT00635024

NCT00112645

NCT00689169

NCT01527032

NCT04521946

NCT00961142

NCT01178645

NCT00683046

NCT02570542

NCT01637766

NCT03852407

NCT01807286

NCT06195891

NCT04150042

NCT00004056

NCT01558960

NCT00114101

NCT00176839

NCT00920153

NCT06425276

NCT00067002

NCT00003816

NCT01237951

NCT01178658

NCT00681044

NCT01702831

NCT00002680

NCT00003815

NCT04473911

NCT00638898

NCT04264078

NCT04264039

NCT00961467

NCT02797470

NCT00669812

NCT02112045

NCT04098393

NCT06158828

NCT00002630

NCT02288741

NCT01274403

NCT02653196

NCT03086993

NCT01702961

NCT00388635

NCT00205764

NCT00083915

NCT00002653

NCT06607458

NCT02766465

NCT01728051

NCT00186966

NCT01936090

NCT01190787

NCT01659658

NCT04682405

NCT05991908

NCT00429026

NCT00968760

NCT00002678

NCT00301860

NCT07199296

NCT01010217

NCT00104975

NCT04370301

NCT04283890

NCT01821781

NCT00004088

NCT00871013

NCT04380376

NCT06207799

NCT04221035

NCT02678572

NCT03615144

NCT04022239

NCT00083551

NCT03615105

NCT02059239

NCT00423709

NCT00046852

NCT07644481

NCT01341262

NCT00176865

NCT00244946

NCT01983969

NCT00185614

NCT02130869

NCT00003199

NCT06679829

NCT00644306

NCT03583424

NCT01277016

NCT00003215

NCT01904136

NCT03856216

NCT01050764

NCT01857934

NCT02072863

NCT00589563

NCT00003789

NCT01983761

NCT01505569

NCT01704716

NCT01335685

NCT06028828

NCT00003086

NCT01063179

NCT01849783

NCT01251172

NCT01807611

NCT00550784

NCT03691376

NCT01350258

NCT03328936

NCT00003727

NCT00792142

NCT00030082

NCT07025824

NCT00027560

NCT01141712

NCT02114502

NCT04282174

NCT00911859

NCT00180791

NCT03259503

NCT00410631

NCT00014508

NCT00427557

NCT00014469

NCT00720447

NCT00004158

NCT07582172

NCT00916058

NCT00916045

NCT01532856

NCT00052884

NCT00556127

NCT02994784

NCT00085449

NCT00936936

NCT01804634

NCT03292263

NCT00003081

NCT00651937

NCT07481669

NCT00043979

NCT03426969

NCT02773550

NCT00014339

NCT00038857

NCT01070862

NCT00427765

NCT01200329

NCT01242267

NCT02756572

NCT00005589

NCT00934154

NCT04903678

NCT04681417

NCT00002730

NCT02707393

NCT03073694

NCT06022939

NCT00577096

NCT00205751

NCT03602235

NCT01413178

NCT00121186

NCT00003080

NCT00103298

NCT00691015

NCT05457556

NCT04994977

NCT00801931

NCT00004165

NCT00985959

NCT00290628

NCT00607984

NCT00629798

NCT01885689

NCT02716805

NCT05436418

NCT00005978

NCT00165139

NCT01237249

NCT01093196

NCT00392691

NCT01998971

NCT00583622

NCT00002750

NCT01690143

NCT00365755

NCT02669615

NCT00281879

NCT06815003

NCT03412565

NCT00004188

NCT01476839

NCT02259348

NCT02097134

NCT00040937

NCT00054353

NCT00550992

NCT00983398

NCT00565968

NCT02700841

NCT00253721

NCT01208766

NCT00421811

NCT00516191

NCT00890500

NCT00383448

NCT02960646

NCT00137995

NCT02589145

NCT00001296

NCT00992446

NCT01035463

NCT00317408

NCT01554852

NCT05115630

NCT04395222

NCT00734149

NCT00253435

NCT01039025

NCT00325416

NCT00307086

NCT00003042

NCT00890552

NCT00089453

NCT00233987

NCT00566098

NCT02443077

NCT04191187

NCT01795430

NCT02251821

NCT00349778

NCT00038831

NCT04008888

NCT00135135

NCT06377540

NCT00899847

NCT02896582

NCT00504101

NCT00985907

NCT01598025

NCT04205240

NCT01142232

NCT01998503

NCT01729091

NCT00507416

NCT07605416

NCT00357565

NCT00521014

NCT01619761

NCT00070187

NCT00577278

NCT00012051

NCT00623077

NCT07085156

NCT01250808

NCT01969435

NCT00405756

NCT00089167

NCT00070200

NCT07364474

NCT02780609

NCT01175356

NCT00539500

NCT00024193

NCT06996119

NCT03792815

NCT00313625

NCT03118492

NCT01824693

NCT01359254

NCT07588360

NCT00003662

NCT03794167

NCT07276386

NCT01548573

NCT01008462

NCT00003661

NCT00276809

NCT01969942

NCT01083316

NCT00060255

NCT01526096

NCT05617625

NCT03393611

NCT00824135

NCT01658904

NCT02917096

NCT00723658

NCT01393769

NCT06172296

NCT00641030

NCT02528877

NCT05636787

NCT00248430

NCT00582933

NCT03821610

NCT01055301

NCT01079936

NCT00004250

NCT00357396

NCT00064337

NCT03346135

NCT00997386

NCT01063439

NCT00523809

NCT00288626

NCT00602706

NCT02497404

NCT00324727

NCT02701673

NCT02199041

NCT02660281

NCT00943293

NCT03061656

NCT00869232

NCT00689936

NCT05508009

NCT01116128

NCT00577668

NCT00217438

NCT02483000

NCT02415413

NCT02447055

NCT00003632

NCT00008307

NCT00477035

NCT01653418

NCT01538472

NCT00716066

NCT00972101

NCT00454480

NCT01293539

NCT00317811

NCT00003631

NCT02880293

NCT00025064

NCT06140966

NCT00008268

NCT01408563

NCT00661544

NCT00574080

NCT02415036

NCT02750254

NCT00008229

NCT00089401

NCT00002810

NCT00790647

NCT06986382

NCT05139004

NCT04339101

NCT00526318

NCT00907452

NCT00008190

NCT00188136

NCT00030719

NCT03795597

NCT00025103

NCT07078721

NCT00472056

NCT02489500

NCT01279694

NCT00843310

NCT04799002

NCT04678401

NCT00925782

NCT06523699

NCT00160355

NCT00003603

NCT00002835

NCT04018937

NCT00827099

NCT00007995

NCT00080886

NCT05031897

NCT01916252

NCT00007852

NCT05903937

NCT01500161

NCT01572688

NCT02195479

NCT00602641

NCT01688401

NCT02390544

NCT00055653

NCT00906113

NCT00417053

NCT01877837

NCT00856388

NCT04384692

NCT06875128

NCT01453088

NCT02206425

NCT00002802

NCT00661336

NCT03829371

NCT05466318

NCT01798004

NCT00305812

NCT05088356

NCT02605421

NCT04812470

NCT01131169

NCT03096782

NCT00003578

NCT00591630

NCT00536601

NCT00001576

NCT05735717

NCT05863845

NCT01652092

NCT00784823

NCT04278040

NCT02790515

NCT03187223

NCT00006747

NCT00436761

NCT07624513

NCT00799539

NCT02866136

NCT01453101

NCT00544570

NCT00498316

NCT00003554

NCT02333162

NCT01745913

NCT00943800

NCT00334932

NCT00202917

NCT03003728

NCT00344526

NCT00948922

NCT00544466

NCT01045460

NCT05674539

NCT00004921

NCT00526734

NCT03506802

NCT06247917

NCT02310997

NCT01005576

NCT00968396

NCT02109861

NCT04412707

NCT03019640

NCT01471067

NCT00943592

NCT00003335

NCT00003399

NCT00003435

NCT00572897

NCT01323517

NCT01529827

NCT00238433

NCT00003425

NCT00618540

NCT00001587

NCT02572492

NCT00003336

NCT01625351

NCT00406978

NCT01410344

NCT00003416

NCT00003413

NCT05477589

NCT00177047

NCT05504291

NCT06287944

NCT00695409

NCT02506959

NCT00536978

NCT00551928

NCT00840684

NCT01518153

NCT06001385

NCT02197221

NCT03417284

NCT03494569

NCT03188172

NCT05228249

NCT00025636

NCT00423514

NCT02353572

NCT02544425

NCT02727803

NCT00505895

NCT01842308

NCT00003402

NCT00002977

NCT00679367

NCT00182793

NCT04530487

NCT01421173

NCT02440464

NCT00003007

NCT02728102

NCT00025649

NCT04937634

NCT00800150

NCT00505921

NCT02614560

NCT00477971

NCT01054196

NCT00574496

NCT01617213

NCT00477815

NCT00075621

NCT00003400

NCT04872595

NCT01921387

NCT00477750

NCT00544115

NCT03570983

NCT04904588

NCT00002945

NCT00003397

NCT00003396

NCT03579927

NCT00573391

NCT07183852

NCT00303849

NCT00074269

NCT00003392

NCT00743288

NCT02507076

NCT00506129

NCT00075608

NCT07259161

NCT05438394

NCT04232085

NCT03579875

NCT01626092

NCT00637767

NCT04982354

NCT00907036

NCT00003353

NCT01119066

NCT00006244

NCT00275015

NCT02867800

NCT01840566

NCT00439556

NCT04466475

NCT03736616

NCT00002973

NCT00789256

NCT00747877

NCT02116959

NCT00002982

NCT03342196

NCT00443235

NCT02331368

NCT00003401

NCT01810588

NCT07396480

NCT03004287

NCT04690192

NCT00004903

NCT00410982

NCT01746173

NCT01526603

NCT03100877

NCT00002989

Known as Alanine nitrogen mustard ChEMBL registry synonym — accepted as the source's own label CHEMBL852
Known as alkeran “Carmustine (B) also known as BCNU Etoposide (E) Cytarabine (A) also known as Ara-C and cytosine arabinoside Melphalan (M) also known as alkeranNCT00574509
2

NCT01923935

NCT00285389

Known as Alkeran hydrochloride ChEMBL registry synonym — accepted as the source's own label CHEMBL852
Known as CB 3025 ChEMBL registry synonym — accepted as the source's own label CHEMBL852
Known as CB 3025 HYDROCHLORIDE ChEMBL registry synonym — accepted as the source's own label CHEMBL852
Known as Evomela ClinicalTrials.gov intervention name — accepted as the source's own label NCT05013437
1

NCT03159702

Known as HDMEL “High-dose chemotherapy using melphalan (HDMEL) is an important component of many conditioning regimens that are given before autologous hematopoietic stem cell transplantation (AHSCT).” PMID 14767498 Apr 2004
Known as Hepzato ChEMBL registry synonym — accepted as the source's own label CHEMBL852
Known as Ivra ChEMBL registry synonym — accepted as the source's own label CHEMBL852
Known as L-PAM “Patients receive melphalan (L-PAM) intrathecally (IT) via lumbar puncture or Ommaya reservoir twice a week for 2 weeks.” NCT00002750
9

“The combination of whole body hyperthermia (WBH) and melphalan (L-PAM) is administered on week 1.” NCT00002973

“Hyperthermic intravenous limb perfusion, HILP; plus Melphalan, L-PAM, NSC-8806.” NCT00001296

“oral melphalan (L-PAM) and oral cyclophosphamide (CTX) on days 22-25 (ABCM)” NCT00002653

“Following 4 weeks of rest, melphalan (L-PAM) is administered over 1 hour.” NCT00003007

“melphalan (L-PAM) before or after total body irradiation (TBI)” NCT00003815

“high-dose melphalan (L-PAM)” NCT00025064

“NSC-614629 L-PAM Melphalan” NCT00002630

“NSC-326231 L-PAM Melphalan” NCT00002730

L-PAM Melphalan, NSC-8806” NCT00002599

Known as L-Phenylalanine Mustard “Intra-Arterial Melphalan (L-Phenylalanine Mustard) Administered in Conjunction With Osmotic Blood-Brain Barrier Disruption in Patients With Brain Malignancies: A Phase I Study” NCT00253721
1

NCT00566696

Known as L-sarcolysin ChEMBL registry synonym — accepted as the source's own label CHEMBL852
Known as Mel “High-dose melphalan (MEL) with autologous stem cell transplant (SCT) is an effective therapy for systemic AL amyloidosis (AL)” NCT01527032
6

“combination with Fludarabine (FLU) and Melphalan (MEL) as a Preparative Regimen” NCT00800150

Melphalan (Mel) dose, adjusted according to the patient's age:” NCT07396480

melphalan (MEL) IV over 1 hour” NCT00550992

“* Melphalan (Mel)” NCT02988466

Melphalan (Mel)” NCT07025824

Melphalan (Mel)” NCT07078721

Known as Melfalán Melfalán, 0,25 mg/Kg oral days 1 to 4 Prednisone, 1 mg/Kg oral days 1 to 4; 0,5 mg/Kg oral days 5 to 8 and 0,25 mg/Kg oral days 9 to 12.” NCT00461747
4

“Bortezomib, 1,3 mg/ m2 iv twice a week in combination with Melfalán 9 mg/m2 oral, days 1 to 4 and Prednisone, 60 mg/m2 oral, days 1 to 4” NCT00652041

“Melfalan used outside ofcurrent indication” NCT04817956

“Busulfan and Melfalan (BUMEL)” NCT02727387

NCT01025778

Known as Melphalan (Alkeran) “Melphalan (Alkeran®)” NCT00997386
4

“Melphalan (Alkeran™)” NCT02128230

Melphalan (Alkeran)NCT01877837

“Melphalan - Alkeran” NCT02148913

“Melphalan=Alkeran” NCT00516191

Known as Melphalan HCL “Patients will be randomized to receive 100 mg/m2 of Melphalan HCL for Injection (Propylene Glycol-Free) on Day -3 and Alkeran for Injection on Day -2 prior to ASCT.” NCT00925782
2

Melphalan HCl for Injection has been approved by NMPA as a standard conditioning drug for ASCT in MM patients.” NCT06425276

“High-Dose Melphalan HCL for Injection (Propylene Glycol-Free)” NCT01660633

Known as Melphalan hydrochloride “Drug Name: melphalan hydrochloride The dosage of different dosage groups were: 9 mg/m2; 18 mg/m2; 27 mg/m2; 40 mg/m2 Administration frequency: once for each subject” NCT05438394
5

“Drug: Melphalan hydrochlorideNCT01293539

“Drug: Melphalan hydrochlorideNCT01688401

“Drug: Melphalan HydrochlorideNCT03417284

NCT03192397

NCT03128359

Known as Melphalan Hydrochloride for Injection “Drug: Melphalan Hydrochloride for InjectionNCT06425276
Known as Melphalan Ideogen “The present study aims to combine high-dose melphalan (Melphalan Ideogen) with treosulfan (Trecondi® Ideogen), a well established bifunctional alkylating agent.” NCT05636787
Known as NCI-C04853 ChEMBL registry synonym — accepted as the source's own label CHEMBL852
Known as NSC-241286 ChEMBL registry synonym — accepted as the source's own label CHEMBL852
Known as NSC-326231 NSC-326231 L-PAM Melphalan” NCT00002730
Known as NSC-614629 NSC-614629 L-PAM Melphalan” NCT00002630
Known as NSC-8806 “Hyperthermic intravenous limb perfusion, HILP; plus Melphalan, L-PAM, NSC-8806.” NCT00001296
1

“L-PAM Melphalan, NSC-8806NCT00002599